Pilot runs in Europe and South America show breakthrough efficiency in monoclonal antibody production with unprecedented cost savings and scalability using Stämm's bubble-free continuous laminar flow bioreactor: the Bioprocessor.

SAN FRANCISCO, Jan. 14, 2025 /PRNewswire/ -- Stämm unveiled breakthrough results of its continuous bioreactor for monoclonal antibody production with pilot studies in Germany, Switzerland, and Argentina. It achieved a minimum of 15x greater volumetric productivity, projecting up to 50x during 2025. It also consistently evidenced up to 4x cellular density and specific productivity. The Bioprocessor, a plug-and-play desktop unit, cuts costs compared to traditional fed-batch systems and eliminates downtime while maintaining quality, working with both adherent and suspension cultures.

As healthcare faces an increasing demand for therapies, Stämm enables the commercialization of biosimilars and different biologics for chronic and complex diseases such as oncology, inflammation, and immunology-related diseases. The biomanufacturing process for cell and gene therapies also benefits thanks to a high surface to volume ratio, low shear stress, and automation capabilities.

Stämm's closed-system design leverages single-use 3D-printed cartridges for seamless scalability and cost efficiency. With successful pilot implementations completed in under three months, the bioreactor is primed for global deployment and underserved markets. Its enhanced productivity stems from a homogeneous, stress-free environment that ensures consistent optimal conditions, including high gas exchange.

As the industry approaches a patent cliff, Stämm positions itself as an ideal partner in facilitating accessible and scalable biomanufacturing solutions. With early adopter partnerships underway, Stämm's approach is set to redefine biomanufacturing standards and enable next-generation medicines, fostering innovation in biologics production worldwide.

About Stämm

Founded in 2016, Stämm is a biomanufacturing company developing novel, fully automated bioprocessors to transform biologics production. Their continuous, bubble-free manufacturing platform with a novel 3D printed bioreactor enhances yields, reduces costs, and minimizes footprint and energy consumption. Stämm's approach enables a scalable and energy-efficient solution for challenging biologics and cell therapy manufacturing.

Dedicated to making biomanufacturing easy, scalable, and repeatable, Stämm's solutions are decentralizing bioprocesses, thus freeing their partners to focus on the disruptive discoveries that make an impact on people's lives. For more information, please visit Stämm's website at https://www.stamm.bio/

Photo - https://mma.prnewswire.com/media/2597698/Stamm.jpg
Logo - https://mma.prnewswire.com/media/1767252/5115190/Stamm_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/stamms-continuous-bioreactor-increases-antibody-productivity-by-up-to-30x-in-european-and-american-pilots-302350901.html

Images

Tags

More Like This

21st.BIO unveils a new pilot plant facility to accelerate impact of biotech innovations globally

Merck Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing

BPC receives order for four equipment packages for continuous biogas process simulation

21ST.BIO OPENS A MORE SUSTAINABLE AVENUE FOR INDUSTRIAL SCALE DAIRY PROTEIN PRODUCTION

BPC secures order from Spanish Research Institute for enhanced anaerobic digestion research

Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies

EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing